EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

Nadin Rabah, Fatima-Ezzahra Ait Mohand, Nataly Kravchenko-Balasha iD

International Journal of Molecular Sciences · 19.09.2023 · 24 (18) · 14256

DOI: 10.3390/ijms241814256 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.09.2023. Verfasst von Nadin Rabah und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem 91120, Israel. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Signal Transduction, Drug Delivery Systems. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most prevalent and aggressive type of brain cancer, namely, glioblastoma (GBM), is characterized by intra- and inter-tumor heterogeneity and strong spreading capacity, which makes treatment ineffective. A true therapeutic answer is still in its infancy despite various studies that have made significant progress toward understanding the mechanisms behind GBM recurrence and its resistance. The primary causes of GBM recurrence are attributed to the heterogeneity and diffusive nature; therefore, monitoring the tumor’s heterogeneity and spreading may offer a set of therapeutic targets that could improve the clinical management of GBM and prevent tumor relapse. Additionally, the blood–brain barrier (BBB)-related poor drug delivery that prevents effective drug concentrations within the tumor is discussed. With a primary emphasis on signaling heterogeneity, tumor infiltration, and computational modeling of GBM, this review covers typical therapeutic difficulties and factors contributing to drug resistance development and discusses potential therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsSignal TransductionDrug Delivery SystemsHumansBlood-Brain BarrierAnimalsAntineoplastic AgentsNeoplasm InvasivenessDrug Resistance, Neoplasm

Stichwörter der Autor:innen

GBM signalingblood–brain barrier (BBB)glioblastomaheterogeneityinvasionrecurrencetargeted therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • The Institute of Biomedical and Oral Research, Hebrew University of Jerusalem, Jerusalem 91120, Israel.

ORCID-Profile: Nataly Kravchenko-Balasha

Förderung

  • Hebrew University of Jerusalem

Zitieren

APA

Rabah, N., Ait Mohand, F. E., & Kravchenko-Balasha, N. (2023). Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers. International Journal of Molecular Sciences, 24(18), 14256. https://doi.org/10.3390/ijms241814256

Vancouver

Rabah N, Ait Mohand FE, Kravchenko-Balasha N. Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers. International Journal of Molecular Sciences. 2023;24(18):14256. doi:10.3390/ijms241814256

BibTeX
@article{Rabah2023,
  author = {Rabah, Nadin and Ait Mohand, Fatima-Ezzahra and Kravchenko-Balasha, Nataly},
  title = {Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {18},
  pages = {14256},
  doi = {10.3390/ijms241814256}
}
Kostenlos starten →